AgricultureTop Companies
Agriculture

Top Agarose Resin Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

Industry

Agriculture

Published

Jan 2026

Share:

Agriculture

Top Agarose Resin Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

$3,590

Choose License Type

Only one user can use this report

Additional users can access this report

You can share within your company

Company Contents

Quick Facts & Snapshot

2025 Market Size (US$)
1.29 Billion
2026 Forecast (US$)
1.39 Billion
2032 Forecast (US$)
2.13 Billion
CAGR (2025-2032)
7.40%

Summary

The Agarose Resin market is in a sustained growth phase, supported by rising biopharma R&D, chromatography adoption, and vaccine-scale manufacturing. Leading Agarose Resin market companies consolidate share through premium affinity resins and integrated purification platforms. With market size reaching US$ 1.29 Billion in 2025 and a 7.40% CAGR to 2032, competition intensifies around high-capacity, single-use, and GMP-compliant solutions.

2025 Revenue of Top Agarose Resin Suppliers
ReportMines Logo

Source: Secondary Information and ReportMines Research Team - 2026

Ranking Methodology

Rankings of Agarose Resin market companies are derived from a composite score blending quantitative and qualitative indicators. Core metrics include estimated 2025 agarose chromatography revenue, three-year revenue growth, and share of large biologics and vaccine purification projects. We also assess installed base in commercial bioprocess facilities, breadth of agarose-based affinity and ion-exchange portfolios, and proprietary technology differentiation, such as ligand engineering and high-flow matrices. Service coverage is evaluated through global GMP support, validation assistance, and security-of-supply programs. Additional weight is given to innovation intensity, measured via R&D spend, patent activity, and partnerships with CDMOs and biopharma innovators. Each company receives normalized scores across criteria, with revenue and technology leadership contributing the highest weights, followed by geographic reach and long-term supply or lifecycle service capabilities. The final ranking reflects relative competitive position in the global Agarose Resin market rather than total corporate size.

Top 10 Companies in Agarose Resin

1
Cytiva (Danaher Corporation)
HiTrap, HiPrep, Sepharose-based legacy lines, MabSelect affinity resins
North America, Europe, Asia Pacific
Marlborough, USA
Protein purification, mAbs, vaccines, cell and gene therapy
Global leader with broadest installed base in commercial biologics purification; premium pricing backed by strong GMP services
Capacity expansions in agarose resin manufacturing, new high-capacity Protein A lines, long-term supply deals with top CDMOs
US$ 410.00 Million
2
Sartorius AG
ProSep, Sartobind, high-throughput agarose and mixed-mode resins
Europe, North America, China
Göttingen, Germany
Bioprocessing, mAbs, biosimilars, novel modalities
Fast-growing challenger offering integrated hardware-resin solutions and strong process development support
Integration of agarose resins with single-use systems, co-development agreements with leading biosimilar manufacturers
US$ 210.00 Million
3
Merck KGaA (MilliporeSigma)
Eshmuno, Fractogel, affinity and ion-exchange agarose matrices
North America, Europe, Asia Pacific
Darmstadt, Germany
Biopharma, vaccine purification, viral vectors
Top-tier player with strong regulatory track record and end-to-end bioprocess offering
Portfolio refresh in high-flow agarose resins, targeted investments in viral vector purification solutions
US$ 190.00 Million
4
Bio-Rad Laboratories, Inc.
Bio-Gel, Nuvia, mixed-mode and affinity agarose resins
North America, Europe, Japan
Hercules, USA
Research chromatography, process-scale purification, analytical workflows
Strong in research and pilot scale, expanding presence in commercial manufacturing environments
Launch of higher-throughput process resins, expansion of OEM partnerships with system integrators
US$ 95.00 Million
5
TOYOBO Co., Ltd.
TOYOPEARL agarose-based resins
Japan, broader Asia, selected US and EU accounts
Osaka, Japan
Bioprocess purification, enzyme and biomolecule separation
Specialist with strong technology in high-capacity ion-exchange and niche affinity applications
New ligands for continuous chromatography; localization of technical support in Europe and North America
US$ 60.00 Million
6
Purolite (an Ecolab company)
Praesto Protein A and ion-exchange agarose resins
Europe, North America, rapidly growing presence in Asia
King of Prussia, USA
Biopharma, enzyme immobilization, specialty separations
Agile innovator in Protein A and next-generation affinity chemistries with competitive cost positioning
Capacity scale-up for Protein A resins, collaboration with CDMOs on intensified processing
US$ 55.00 Million
7
Repligen Corporation
OPUS columns with integrated agarose resins, custom affinity supports
North America, Europe
Waltham, USA
Bioprocessing, continuous biomanufacturing, mAbs
Strong niche position combining agarose resins with high-performance column technologies
Expansion of pre-packed column formats, partnerships for continuous bioprocessing platforms
US$ 40.00 Million
8
Bio-Works Technologies AB
WorkBeads agarose-based resins
Europe, North America, select Asia Pacific markets
Uppsala, Sweden
Emerging biopharma, CDMOs, research institutes
Innovation-focused SME with differentiated support for small and mid-size biologics developers
Channel expansion via distributors, focus on mid-scale bioprocess customers and flexible packaging
US$ 22.00 Million
9
ABT Beads (Agarose Bead Technologies)
ABT agarose affinity and activated resins
Europe, North America, Latin America
Madrid, Spain
Affinity chromatography, enzyme immobilization, diagnostics
Specialist supplier of tailored agarose beads with flexible manufacturing for niche applications
Broader OEM supply deals, customized ligand development programs for bioprocess customers
US$ 18.00 Million
10
Takara Bio Inc.
Agarose resins for viral vector and nucleic acid purification
Japan, North America, Europe
Kusatsu, Japan
Gene therapy, cell therapy, research reagents
Focused player leveraging agarose resin capabilities within a broader advanced therapies portfolio
New agarose-based tools for AAV and lentiviral purification, integration with gene therapy platforms
US$ 15.00 Million

Source: Secondary Information and ReportMines Research Team - 2026

Detailed Company Profiles

1

Cytiva (Danaher Corporation)

Cytiva is the dominant global provider of chromatography resins and bioprocess solutions serving commercial biologics, vaccines, and advanced therapies manufacturers.

Key Financials: 2025 Agarose Resin revenue US$ 410.00 Million; estimated segment CAGR 7.80%.
Flagship Products: HiTrap, HiPrep, MabSelect Protein A resins
2025-2026 Actions: Expanded agarose resin facilities in Europe, signed multi-year supply agreements with leading CDMOs and vaccine manufacturers.
Three-line SWOT: Extensive installed base and robust GMP support; Premium pricing versus regional competitors; Opportunity—capacity constraints at rivals drive share gain.
Notable Customers: Lonza, Samsung Biologics, Pfizer
2

Sartorius AG

Sartorius delivers integrated bioprocess platforms, coupling single-use hardware with advanced agarose resin portfolios for mAbs and biosimilar production.

Key Financials: 2025 Agarose Resin revenue US$ 210.00 Million; R&D intensity about 8.50% of bioprocess revenue.
Flagship Products: ProSep Protein A, Sartobind, ion-exchange agarose resins
2025-2026 Actions: Launched next-generation high-capacity Protein A agarose resins and deepened collaborations with biosimilar manufacturers in Asia.
Three-line SWOT: Strong integration of hardware and consumables; Dependence on biopharma capex cycles; Opportunity—biosimilar wave in emerging markets.
Notable Customers: Biocon Biologics, Fujifilm Diosynth, Novartis
3

Merck KGaA (MilliporeSigma)

Merck KGaA provides end-to-end bioprocess solutions with a strong agarose resin franchise for monoclonal antibodies, vaccines, and viral vectors.

Key Financials: 2025 Agarose Resin revenue US$ 190.00 Million; operating margin around 24.00%.
Flagship Products: Eshmuno Protein A, Fractogel, ion-exchange agarose resins
2025-2026 Actions: Introduced higher-flow agarose matrices and invested in viral vector purification capacity aligned with cell and gene therapy growth.
Three-line SWOT: Broad regulatory track record and high reliability; Portfolio complexity may slow launches; Opportunity—advanced therapies and vector demand.
Notable Customers: Moderna, Sanofi, WuXi Biologics
4

Bio-Rad Laboratories, Inc.

Bio-Rad offers versatile agarose resins for research to process scale, supporting chromatography workflows in pharma, biotech, and academic labs.

Key Financials: 2025 Agarose Resin revenue US$ 95.00 Million; chromatography business CAGR about 6.90%.
Flagship Products: Bio-Gel, Nuvia agarose, mixed-mode affinity resins
2025-2026 Actions: Expanded process-scale resin portfolio and strengthened OEM agreements for integration with third-party chromatography skids.
Three-line SWOT: Strong research brand recognition; Smaller presence in large commercial plants; Opportunity—upgrade path from R&D to pilot and clinical.
Notable Customers: Amgen, academic core facilities, regional CDMOs
5

TOYOBO Co., Ltd.

TOYOBO focuses on high-performance agarose-based resins used in ion-exchange and affinity chromatography across biopharma and enzyme markets.

Key Financials: 2025 Agarose Resin revenue US$ 60.00 Million; Asia-focused growth around 7.20% annually.
Flagship Products: TOYOPEARL ion-exchange, affinity agarose resins
2025-2026 Actions: Developed new ligands targeting continuous chromatography and bolstered technical support centers in Europe and North America.
Three-line SWOT: Strong technology base in high-capacity resins; Limited brand visibility outside Asia; Opportunity—continuous bioprocess adoption globally.
Notable Customers: Japanese pharma majors, Korean biosimilar producers, regional CDMOs
6

Purolite (an Ecolab company)

Purolite supplies Praesto agarose resins, emphasizing Protein A and specialty affinity products for cost-efficient large-scale mAb purification.

Key Financials: 2025 Agarose Resin revenue US$ 55.00 Million; Protein A segment growing about 9.10% annually.
Flagship Products: Praesto Protein A, Praesto ion-exchange agarose
2025-2026 Actions: Scaled up Protein A resin manufacturing and collaborated with CDMOs on intensified, high-productivity purification trains.
Three-line SWOT: Competitive cost-performance balance; Smaller service network than top three; Opportunity—biologics capacity additions in Asia and Latin America.
Notable Customers: Global CDMOs, regional biosimilar companies, vaccine manufacturers
7

Repligen Corporation

Repligen integrates agarose resins into pre-packed columns, supporting intensified and continuous bioprocessing for mAb and recombinant protein makers.

Key Financials: 2025 Agarose Resin revenue US$ 40.00 Million; column and filtration portfolio CAGR about 10.20%.
Flagship Products: OPUS pre-packed columns with agarose, custom affinity resins
2025-2026 Actions: Expanded OPUS column formats and partnered on fully continuous downstream processing solutions with major system suppliers.
Three-line SWOT: Strong reputation in high-performance columns; Limited standalone resin branding; Opportunity—continuous biomanufacturing adoption curve.
Notable Customers: Roche, Eli Lilly, leading global CDMOs
8

Bio-Works Technologies AB

Bio-Works is a growth-stage supplier of WorkBeads agarose resins targeting emerging biopharma and flexible mid-scale manufacturing needs.

Key Financials: 2025 Agarose Resin revenue US$ 22.00 Million; double-digit revenue CAGR around 12.50%.
Flagship Products: WorkBeads Protein A, WorkBeads ion-exchange agarose
2025-2026 Actions: Broadened distributor network and introduced packaging tailored for clinical and niche commercial manufacturing volumes.
Three-line SWOT: Agile product development and customer service; Smaller manufacturing scale; Opportunity—supporting rapidly growing small biotechs and CDMOs.
Notable Customers: European CDMOs, emerging biologics firms, academic spin-offs
9

ABT Beads (Agarose Bead Technologies)

ABT Beads specializes in customized agarose beads and affinity resins serving bioprocess, diagnostics, and enzyme immobilization applications worldwide.

Key Financials: 2025 Agarose Resin revenue US$ 18.00 Million; niche custom projects growing 8.30% annually.
Flagship Products: ABT affinity agarose, activated agarose beads
2025-2026 Actions: Secured OEM supply deals and expanded custom ligand development services for tailored purification processes.
Three-line SWOT: High flexibility and customization capability; Lower global brand recognition; Opportunity—bespoke solutions for complex biologics pipelines.
Notable Customers: Diagnostics OEMs, specialty enzyme producers, regional biopharma companies
10

Takara Bio Inc.

Takara Bio leverages agarose resin technologies mainly for gene and cell therapy workflows and advanced research applications worldwide.

Key Financials: 2025 Agarose Resin revenue US$ 15.00 Million; advanced therapies tools segment CAGR about 11.40%.
Flagship Products: Agarose resins for viral vector purification, nucleic acid cleanup
2025-2026 Actions: Introduced specialized agarose resins for AAV and lentiviral purification integrated into broader gene therapy platforms.
Three-line SWOT: Strong positioning in advanced therapies; Small share in traditional mAb purification; Opportunity—accelerating gene and cell therapy pipelines.
Notable Customers: Gene therapy developers, cell therapy centers, leading research institutes

SWOT Leaders

Cytiva (Danaher Corporation)

SWOT Snapshot

SWOT
Strengths

Largest installed base, comprehensive agarose portfolio, strong GMP service and validation network across major biopharma hubs.

Weaknesses

Premium pricing and long qualification cycles may discourage cost-sensitive or smaller biopharma customers.

Opportunities

Biologics and vaccine capacity expansion, especially in emerging markets and government-backed manufacturing initiatives.

Threats

Price pressure from regional agarose suppliers and risk of supply-chain disruptions affecting mission-critical resins.

Sartorius AG

SWOT Snapshot

SWOT
Strengths

Integrated single-use and resin offering, strong presence in biosimilars, and advanced process development capabilities.

Weaknesses

Exposure to bioprocess capex slowdown and competition from other integrated platform providers.

Opportunities

Rapid biosimilar uptake in Asia and Latin America and growing adoption of intensified bioprocessing.

Threats

Regulatory or reimbursement shifts impacting biosimilar investments and aggressive pricing from local competitors.

Merck KGaA (MilliporeSigma)

SWOT Snapshot

SWOT
Strengths

Trusted regulatory track record, broad chromatography range, and strong position in viral vector purification.

Weaknesses

Complex product portfolio may slow commercialization of new agarose innovations and confuse buyers.

Opportunities

Growth of cell and gene therapies, vector manufacturing expansions, and long-term supply partnerships.

Threats

Increasing competition in Protein A and ion-exchange resins and potential raw-material cost volatility.

Agarose Resin Market Regional Competitive Landscape

North America remains the largest revenue contributor for Agarose Resin market companies, anchored by major biopharma clusters in the United States and Canada. Cytiva, Merck KGaA, and Bio-Rad dominate GMP installations, supported by strong regulatory alignment and recurrent investments in monoclonal antibody, vaccine, and gene therapy facilities.

Europe shows a balanced mix of large pharma, biosimilars, and CDMOs, driving robust demand for premium agarose resins. Sartorius AG, Merck KGaA, and Cytiva lead, while Bio-Works and ABT Beads gain traction with mid-size biotechs seeking flexible support and customized ligands for complex biologics purification.

Asia Pacific is the fastest-growing region for Agarose Resin market companies, fueled by expanding biologics capacity in China, South Korea, India, and Japan. Cytiva, Sartorius, and Merck face increasing competition from TOYOBO and Purolite, as regional biosimilar producers demand competitively priced, high-performance Protein A and ion-exchange resins.

Japan and broader East Asia feature strong domestic players like TOYOBO and Takara Bio, which leverage local relationships and technical service proximity. These companies compete effectively with global leaders in niche applications, including advanced therapies and enzyme processes, while gradually expanding exports to Europe and North America.

Latin America and the Middle East and Africa remain emerging but strategically important markets where Agarose Resin market companies pursue early positioning. Cytiva, Merck KGaA, and Purolite typically enter via partnerships with local distributors and regional CDMOs, aligning with government-led initiatives to localize biologics and vaccine manufacturing capacity.

In Central and Eastern Europe, agile suppliers such as Bio-Works Technologies and ABT Beads strengthen presence through distributor networks and collaborations with regional CDMOs. These markets prioritize cost-effective yet high-quality agarose solutions, creating opportunities for mid-tier players to challenge the leading multinational incumbents.

Agarose Resin Market Emerging Challengers & Disruptive Start-Ups

Emerging Challengers & Disruptive Start-Ups

ResiFlux Biotechnologies
Disruptor
USA

Develops high-flow agarose resins optimized for continuous chromatography, targeting intensified bioprocessing with lower buffer consumption and smaller footprints.

NanoMatrix Bioprocess
Disruptor
Germany

Combines agarose backbones with nanoengineered ligands to boost binding capacity for complex biologics, improving yield in challenging purification steps.

Agarion Life Sciences
Disruptor
India

Offers cost-competitive agarose Protein A and ion-exchange resins tailored for regional biosimilar manufacturers, with strong local technical support services.

BioSephix Innovations
Disruptor
Belgium

Focuses on sustainable agarose production and recyclable chromatography media, appealing to biopharma companies with aggressive environmental and ESG targets.

VectorPur Labs
Disruptor
South Korea

Specializes in agarose resins for viral vector and mRNA platforms, integrating data-driven optimization tools for faster process development cycles.

Agarose Resin Market Future Outlook & Key Success Factors (2026-2032)

From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Agarose Resin market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.

Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Agarose Resinmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.

Frequently Asked Questions

Find answers to common questions about this company report.